DEA Moves to Temporarily Schedule Synthetic Kratom Derivatives 7-OH

The Drug Enforcement Administration issued two Notices of Intent on July 1, 2026, to begin temporarily scheduling 7-hydroxymitragynine (7-OH) and three related synthetic substances under Schedule I of the Controlled Substances Act. The action specifically targets concentrated and chemically manipulated kratom products while explicitly preserving access to traditional natural leaf kratom.

What Is Being Scheduled

The DEA's action focuses on four substances: 7-hydroxymitragynine above a specified concentration threshold, mitragynine pseudoindoxyl (MP), MGM-15, and MGM-16. These compounds represent synthesized or highly concentrated derivatives of kratom's naturally occurring alkaloids, often found in products marketed as enhanced extracts, candies, tablets, and liquid shots.

The temporary scheduling order does not apply to botanical kratom products containing naturally occurring 7-OH below the specified threshold. This distinction reflects the DEA's assessment that chemically manipulated products pose substantially greater risks than traditional preparations.

Public Health Rationale

The scheduling action follows a formal recommendation from the FDA, which concluded that these substances present an imminent hazard to public safety. HHS Secretary Robert F. Kennedy Jr. endorsed the move, stating that "7-OH, MP, MGM-15, and MGM-16 are dangerous opioids that fuel addiction and put American lives at risk."

The DEA's notice cites accumulating evidence of abuse potential, adverse health effects, and the absence of accepted medical use for these specific compounds. Emergency department visits and poison control center calls involving enhanced kratom products have increased substantially in recent years, prompting regulatory concern.

Timeline and Implementation

The Notices of Intent published in the Federal Register on July 1 initiate a 30-day comment period. Following this period, the DEA may issue a temporary scheduling order effective for two years, with a possible one-year extension. During this time, the agency will gather additional data to support permanent scheduling under the standard administrative process.

Once the temporary order takes effect—potentially as early as August 2026—possession, distribution, and manufacture of the scheduled substances will become federal crimes carrying Schedule I penalties. The DEA has indicated it will prioritize enforcement against commercial manufacturers and distributors rather than individual consumers.

Industry and Advocacy Responses

The American Kratom Association, which has long advocated for regulation rather than prohibition, expressed qualified support for the action. The organization emphasized that the DEA's targeted approach validates its position that natural kratom leaf should remain accessible while enhanced products require stricter oversight.

Some harm reduction advocates have raised concerns that scheduling could drive the market further underground, potentially increasing risks from unregulated products. Others note that the two-year temporary window provides opportunity for researchers to gather safety and efficacy data that could inform longer-term policy.

Implications for Consumers

For individuals using kratom products, the regulatory change creates new legal risks specifically for enhanced extracts and concentrated formulations. Natural leaf products that fall below the 7-OH concentration threshold will remain legal under federal law, though state and local regulations vary considerably.

The action highlights the importance of understanding product composition. Consumers should be aware that products labeled as "extracts," "shots," or "enhanced" may fall under the scheduled category, while traditional powdered leaf likely will not.

Broader Context

The 7-OH scheduling represents the latest development in the federal government's evolving approach to kratom regulation. The FDA has previously attempted to schedule kratom's primary alkaloids, mitragynine and 7-hydroxymitragynine, but withdrew that proposal following public outcry and congressional pressure.

This more targeted approach—focusing on synthetic derivatives and concentrated products while exempting natural botanical material—may establish a template for regulating other plant-based substances with abuse potential. The outcome will likely influence how policymakers address emerging psychoactive compounds in the future.

For people struggling with opioid use disorder, this regulatory action underscores the importance of accessing evidence-based treatment options rather than unregulated substances. Comprehensive addiction treatment programs offer medically supervised approaches that address both the physical and psychological dimensions of dependence.